Palonosetron Reig Jofre Uk

Palonosetron, the active ingredient in Palonosetron Reig Jofre Uk, is a serotonin 5‑HT3 receptor antagonist presented as a sterile injectable solution for intravenous use. It is used to prevent nausea and vomiting associated with chemotherapy and surgery in adult patients.

GNH USA supplies Palonosetron Reig Jofre Uk as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Palonosetron is a selective 5‑HT3 receptor antagonist indicated for the prevention of chemotherapy‑induced and postoperative nausea and vomiting. - Chemotherapy‑induced nausea and vomiting (CINV): helps reduce the incidence of acute and delayed vomiting after highly emetogenic chemotherapy. - Moderate emetogenic chemotherapy (MEC)‑induced nausea and vomiting: provides effective prophylaxis for patients receiving moderate risk regimens. - Post‑operative nausea and vomiting (PONV): reduces the frequency of nausea and vomiting following general anesthesia. - Radiotherapy‑induced nausea and vomiting: used as part of anti‑emetic regimens for patients undergoing radiation therapy that may trigger emesis.

Palonosetron may cause a range of adverse reactions, most of which are mild to moderate in intensity.

Common Side Effects: - Headache: mild to moderate headache reported in clinical studies. - Constipation: transient reduction in bowel movements. - Fatigue: general feeling of tiredness. - Dizziness: occasional light‑headed sensation. - Injection site reactions: mild erythema or discomfort at the site of administration.

Serious or Rare Side Effects: - QT interval prolongation: may affect cardiac repolarisation, requiring ECG monitoring in susceptible patients. - Severe hypersensitivity: anaphylactic reactions including rash, swelling, or respiratory distress. - Serotonin syndrome: rare but possible when combined with other serotonergic agents. - Cardiac arrhythmias: uncommon ventricular arrhythmias in high‑risk individuals. - Severe constipation or intestinal obstruction: rare gastrointestinal complications requiring medical attention.

When using Palonosetron, clinicians should consider several safety aspects to minimise risk. - Cardiac monitoring: assess baseline ECG in patients with known QT prolongation or electrolyte disturbances. - Concomitant serotonergic drugs: evaluate risk of serotonin syndrome when used with other serotonergic agents. - Electrolyte balance: correct hypokalaemia, hypomagnesaemia or hypocalcaemia before administration. - Pregnancy and lactation: use only if the potential benefit outweighs the risk; data are limited. - Renal or hepatic impairment: dose adjustment may be required; monitor organ function. - Store at ambient temperature: keep below 25°C, protect from moisture and light, and retain in original packaging.

Palonosetron has a low potential for drug‑drug interactions, but certain combinations warrant caution.

Major Interactions (Avoid): - Other QT‑prolonging agents: concurrent use may increase risk of cardiac arrhythmias. - Strong CYP3A4 inhibitors/inducers: may alter plasma levels of palonosetron, though clinical relevance is limited.

Moderate Interactions (Monitor Closely): - Serotonergic medications (e.g., SSRIs, tramadol): monitor for signs of serotonin syndrome. - Anticholinergic drugs: may exacerbate constipation. - Diuretics causing electrolyte loss: watch for increased QT prolongation risk. - Antifungal azoles: potential additive effect on QT interval. - Anesthetic agents: observe for enhanced hypotensive responses.